High Growth Tech Stocks To Watch In February 2025

The United States market has experienced a positive trend, rising 1.2% over the last week and climbing 24% in the past year, with earnings anticipated to grow by 15% annually in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	29.07%	27.57%	★★★★★★
Ardelyx	21.09%	55.29%	★★★★★★
AVITA Medical	29.48%	53.36%	★★★★★★
TG Therapeutics	29.48%	45.20%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Travere Therapeutics	30.33%	61.73%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.83%	59.08%	★★★★★★
Alvotech	31.17%	100.18%	★★★★★★
Lumentum Holdings	21.25%	118.58%	★★★★★★

Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Zai Lab (NasdaqGM:ZLAB)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zai Lab Limited focuses on developing and commercializing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience with a market cap of approximately $3.16 billion.

Operations: Zai Lab Limited generates revenue primarily from its biotechnology segment, amounting to $355.75 million. The company is involved in developing therapies across several medical fields, including oncology and autoimmune disorders.

Zai Lab's trajectory in the high-growth tech landscape is marked by significant strides in biotechnology, particularly through its innovative drug developments and strategic alliances. With an expected revenue growth of 30.5% per year, Zai Lab outpaces the US market average significantly. The company's recent acceptance of a New Drug Application by China’s National Medical Products Administration for KarXT highlights its commitment to addressing schizophrenia with novel treatments, reflecting a broader impact on healthcare technology and patient outcomes. Furthermore, collaborations like the one with Vertex Pharmaceuticals for povetacicept underline Zai Lab’s role in expanding therapeutic options across Asia, leveraging R&D to foster regional medical advancements. These efforts are set against a backdrop of unprofitability; however, earnings are forecast to surge by 61.68% annually as these initiatives begin to bear fruit, positioning Zai Lab as a pivotal player in transforming patient care through technology.

• Navigate through the intricacies of Zai Lab with our comprehensive health report here.

• Review our historical performance report to gain insights into Zai Lab's's past performance.

Legend Biotech (NasdaqGS:LEGN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications globally, with a market cap of approximately $6.68 billion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to $520.18 million. Operating in the United States, China, and internationally, it focuses on developing innovative cell therapies for oncology and other medical fields.

Legend Biotech, with its recent executive reshuffles and groundbreaking clinical results, exemplifies a dynamic player in the high-growth biotechnology sector. The company's revenue is projected to climb by 30.4% annually, significantly outstripping the US market's growth rate of 8.9%. This surge is supported by innovative therapies like CARVYKTI®, which demonstrated superior outcomes in multiple myeloma treatments at recent trials, marking a significant advancement in oncology care. Despite current unprofitability, earnings are expected to rocket by 56.5% per year over the next three years as these innovations begin to pay off financially and therapeutically for patients worldwide.

• Click here to discover the nuances of Legend Biotech with our detailed analytical health report.

• Understand Legend Biotech's track record by examining our Past report.

Take-Two Interactive Software (NasdaqGS:TTWO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Take-Two Interactive Software, Inc. is a global developer, publisher, and marketer of interactive entertainment solutions with a market cap of $36.85 billion.

Operations: Take-Two generates revenue primarily through its publishing segment, which accounts for $5.45 billion.

Despite recent quarterly losses, Take-Two Interactive Software shows promising prospects with a robust annual revenue growth of 15.1%, outpacing the U.S. market average of 8.9%. The company's strategic focus on expanding its gaming franchises, as evidenced by the upcoming PGA TOUR 2K25 release featuring significant enhancements and celebrity endorsements, underscores its innovative approach in a competitive sector. Moreover, Take-Two's commitment to R&D is evident from its substantial investment in new game development and technology upgrades to enhance player experience and engagement across various platforms. With earnings expected to grow by an impressive 93.9% annually, the firm is positioning itself for profitability and sustained growth amidst challenging market conditions.

• Click to explore a detailed breakdown of our findings in Take-Two Interactive Software's health report.

• Evaluate Take-Two Interactive Software's historical performance by accessing our past performance report.

Make It Happen

• Delve into our full catalog of 230 US High Growth Tech and AI Stocks here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com